Development-stage biotech Targacept (TRGT)
may have once had a bright future and a nearly $30 share price, but
those days are long past. With yet another clinical disappointment, it
seems fair to ask whether Targacept's entire research direction is
fundamentally flawed and whether the company can use the capital it has
left to find a new path … or if shareholders would be better served by
the company simply closing up shop and returning the cash.
Please continue here:
Targacept Looking Like A Dead End
No comments:
Post a Comment